NorthWest Biotherapeutics Inc (NWBO)

[abc1212]

Alzheimers drug donanemab rejected by Nice

https://news.sky.com/story/pioneering-alzheimers-drug-rejected-for-widespread-use-in-nhs-in-england-13239378

The announcement comes as the UK's medicines regulator said that donanemab could be licensed for use in the UK.

However, the health spending watchdog, the National Institute of Health and Care Excellence (NICE), said that it "does not currently demonstrate value for the NHS".

It is the second time a new Alzheimer's treatment has been rejected by NICE in a matter of months.

.

"Our independent committee looked at all the available evidence, including the benefits for carers.

"This shows donanemab could slow down cognitive decline by four to seven months, but this is just not enough benefit to justify the additional cost to the NHS.

"The cost-effectiveness estimate for donanemab is five to six times above what NICE normally considers an acceptable use of NHS resources.

.